A Phase 1 Randomized Observer-Blind Dose-Ranging Study To Evaluate The Safety Tolerability And Immunogenicity Of Modified RNA Vaccine Candidates Against Pandemic Influenza In Healthy Adults

Brief description of study

This vaccine trial will evaluate the safety, tolerability, and effectiveness of an investigational vaccine against bird flu, also known as Avian Influenza or H5N1 virus. This vaccine is being studied to protect against Bird Flu in adults Our study team will be enrolling participants between the ages of 65 through 84. If you are eligible and agree to participate, you will be randomly assigned to 1 of 2 study groups:

Investigational vaccine on Days 1 and 21, or
Placebo injection on Days 1 and 21

Investigational vaccine on Days 1 and 21, or
Placebo injection on Days 1 and 21

If you decide to participate in this study, you would be asked to complete a minimum of 1 in-person screening visit and 7 in-person study visits over a period of approximately 1 year. You will be compensated for each in-person study visit.

Clinical Study Identifier: s24-00800

ClinicalTrials.gov Identifier: NCT06179446

Principal Investigator: Mark J. Mulligan.

Other Investigators: Robert Anwar Pitts, Madeline Alexandra DiLorenzo, Tamia Davis, Angelica Cifuentes Kottkamp, Lalitha Parameswaran, Andrew Banks Fleming, Celia Engelson, Purvi S. Parikh.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies